Abstract:The natural history of COPD is complex, and the disease is best understood as a syndrome resulting from numerous interacting factors throughout the life cycle with smoking being the strongest inciting feature. Unfortunately, diagnosis is often delayed with several longitudinal cohort studies shedding light on the long 'preclinical' period of COPD. It is now accepted that individuals presenting with different COPD phenotypes may experience varying natural history of their disease. This includes its inception, early stages and progression to established disease. Several scenarios regarding lung function course are possible, but it may conceptually be helpful to distinguish between individuals with normal maximally attained lung function in their early adulthood who thereafter experience faster than normal FEV1 decline, and those who may achieve a lower than normal maximally attained lung function. This may be the main mechanism behind COPD in the latter group, as the decline in FEV1 during their adult life may be normal or only slightly faster than normal. Regardless of the FEV1 trajectory, continuous smoking is strongly associated with disease progression, development of structural lung disease and poor prognosis. In developing countries, factors such as exposure to biomass and sequelae after tuberculosis may lead to a more airway‐centred COPD phenotype than seen in smokers. Mechanistically, COPD is characterized by a combination of structural and inflammatory changes. It is unlikely that all patients share the same individual or combined mechanisms given the heterogeneity of resultant phenotypes. Lung explants, bronchial biopsies and other tissue studies have revealed important features. At the small airway level, progression of COPD is clinically imperceptible, and the pathological course of the disease is poorly described. Asthmatic features can further add confusion. However, the small airway epithelium is likely to represent a key focus of the disease, combining impaired subepithelial crosstalk and structural/inflammatory changes. Insufficient resolution of inflammatory processes may facilitate these changes. Pathologically, epithelial metaplasia, inversion of the goblet to ciliated cell ratio, enlargement of the submucosal glands and neutrophil and CD8‐T‐cell infiltration can be detected. Evidence of type 2 inflammation is gaining interest in the light of new therapeutic agents. Alarmin biology is a promising area that may permit control of inflammation and partial reversal of structural changes in COPD. Here, we review the latest work describing the development and progression of COPD with a focus on lung function trajectories, exacerbations and survival. We also review mechanisms focusing on epithelial changes associated with COPD and lack of resolution characterizing the underlying inflammatory processes.

Molecular changes underlying pulmonary emphysema and chronic bronchitis in Chronic Obstructive Pulmonary Disease: An updated review

Epigenetic Modifications and Therapy in Chronic Obstructive Pulmonary Disease (COPD): An Update Review

LSC Abstract – Systemic and Local Metabolomics Profiling Reveals Novel Insights into the Progression of Emphysema

Metabolomics Screening Identifies Reducedl-Carnitine to Be Associated with Progressive Emphysema

Pathological changes in the COPD lung mesenchyme--novel lessons learned from in vitro and in vivo studies.

Systemic Alterations in Neutrophils and Their Precursors in Early-Stage Chronic Obstructive Pulmonary Disease

Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives

Loss Of Peripheral Tolerance In Emphysema Phenotypes, Exacerbations, And Disease Progression

Epithelial and endothelial cell plasticity in chronic obstructive pulmonary disease (COPD)

Integrated Analysis of Metabolomics and Proteomics Datasets Reveals Insights Into the Mechanism of Chronic Obstructive Pulmonary Disease With Chronic-Bronchitis and Emphysema Phenotypes

Natural history and mechanisms of COPD

Chronic obstructive pulmonary disease and the airway microbiome: A review for clinicians

Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies

An Updated Overview of Metabolomic Profile Changes in Chronic Obstructive Pulmonary Disease

COPD Patients Exhibit Distinct Gene Expression, Accelerated Cellular Aging, and Bias to M2 Macrophages

Targeting Biophysical Microenvironment for Improved Treatment of Chronic Obstructive Pulmonary Disease.

The Current Molecular and Cellular Landscape of Chronic Obstructive Pulmonary Disease (COPD): A Review of Therapies and Efforts towards Personalized Treatment

The Heterogeneity of Inflammatory Response and Emphysema in Chronic Obstructive Pulmonary Disease

Lipid Metabolism In Chronic Obstructive Pulmonary Disease

Impact on Airway Remodeling

The Molecular Blueprint for Chronic Obstructive Pulmonary Disease (COPD): A New Paradigm for Diagnosis and Therapeutics